Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 12, 2026 · Filed Feb 18, 2026
Biogen's Head of Pharm Ops and Tech paid $585 out of pocket for Biogen shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$585
Shares × reported transaction price
<$25K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($5.87M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-28. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
6 days after results of Feb 6, 2026, 53 days before results of Apr 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $195.50 on Feb 12, 2026, within 3% of its 52-week high, after an 11% rise over the previous 30 trading days
52-week range $113.38 (Apr 10, 2025) to $201.18 (Feb 6, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $176.40 on Dec 30, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Nicole Murphy's first open-market purchase of BIIB in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
A securities lawsuit naming the company as a defendant was filed on Oct 23, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Gray v. Biogen Inc., docket 1:24-cv-12691, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.8% | +1.0% | −2.8% |
| 30 days | −6.5% | −5.5% | −1.0% |
| 90 days | −1.8% | +6.9% | −8.8% |
| 180 days | +7.7% | +12.6% | −4.8% |
Past results only. Not a forecast.
Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Feb 13 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.